HRP20070577T4 - Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida - Google Patents

Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida Download PDF

Info

Publication number
HRP20070577T4
HRP20070577T4 HR20070577T HRP20070577T HRP20070577T4 HR P20070577 T4 HRP20070577 T4 HR P20070577T4 HR 20070577 T HR20070577 T HR 20070577T HR P20070577 T HRP20070577 T HR P20070577T HR P20070577 T4 HRP20070577 T4 HR P20070577T4
Authority
HR
Croatia
Prior art keywords
image
compound according
derivatives useful
quinazolinone
following formula
Prior art date
Application number
HR20070577T
Other languages
English (en)
Inventor
Ritchie T.J.
Culshaw A.J.
Brain C.T.
Dziadulewicz E.K.
Hart Terance
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32696854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070577(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20070577T3 publication Critical patent/HRP20070577T3/hr
Publication of HRP20070577T4 publication Critical patent/HRP20070577T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Cereal-Derived Products (AREA)

Abstract

Kinazolinonski spoj u slobodnom obliku ili u obliku soli, naznačen time, da je odabran od: 3-(4-klorofenil)-7-hidroksi-2-izopropil-3H-kinazolin-4-onPatent sadrži još 6 patentnih zahtjeva.

Claims (7)

1. Kinazolinonski spoj u slobodnom obliku ili u obliku soli, naznačen time, da je odabran od: 3-(4-klorofenil)-7-hidroksi-2-izopropil-3H-kinazolin-4-on [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
2. Spoj prema zahtjevu 1, naznačen time, da ima sljedeću formulu [image]
3. Spoj prema zahtjevu 1, naznačen time, da ima sljedeću formulu [image]
4. Spoj prema zahtjevu 1, naznačen time, da ima sljedeću formulu [image]
5. Uporaba kinazolinonskog spoja koji je određen u bilo kojem zahtjevu 1 do 4, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti ili stanja, u kojima igra ulogu aktiviranje vaniloid receptora ili ima utjecaja na njih.
6. Kinazolinonski spoj koji je određen u bilo kojem zahtjevu 1 do 4, naznačen time, da se koristi kao farmaceutsko srestvo za liječenje ili prevenciju bolesti ili stanja, u kojima igra ulogu aktiviranje vaniloid receptora ili ima utjecaja na njih.
7. Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 4 u spoju s farmaceutskim nosačem ili razrjeđivačima te opcijski u kombinaciji s drugim farmaceutskim sredstvom.
HR20070577T 2004-06-08 2007-12-20 Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida HRP20070577T4 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0412769.2A GB0412769D0 (en) 2004-06-08 2004-06-08 Organic compounds
PCT/EP2005/006253 WO2005120510A1 (en) 2004-06-08 2005-06-08 Quinazolinone derivatives useful as vanilloid antagonists

Publications (2)

Publication Number Publication Date
HRP20070577T3 HRP20070577T3 (hr) 2008-08-31
HRP20070577T4 true HRP20070577T4 (hr) 2011-10-31

Family

ID=32696854

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070577T HRP20070577T4 (hr) 2004-06-08 2007-12-20 Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida

Country Status (30)

Country Link
US (4) US7960399B2 (hr)
EP (1) EP1755606B2 (hr)
JP (2) JP4703650B2 (hr)
KR (2) KR101018607B1 (hr)
CN (1) CN1956721B (hr)
AT (1) ATE376833T1 (hr)
AU (2) AU2005251476C1 (hr)
BR (1) BRPI0511933B8 (hr)
CA (1) CA2567821C (hr)
CY (1) CY1107846T1 (hr)
DE (1) DE602005003128T3 (hr)
DK (1) DK1755606T4 (hr)
EC (2) ECSP067067A (hr)
ES (1) ES2293584T5 (hr)
GB (1) GB0412769D0 (hr)
HK (1) HK1105577A1 (hr)
HR (1) HRP20070577T4 (hr)
IL (1) IL179532A (hr)
MA (1) MA28685B1 (hr)
MX (1) MXPA06014249A (hr)
NO (1) NO338181B1 (hr)
NZ (1) NZ551630A (hr)
PL (1) PL1755606T5 (hr)
PT (1) PT1755606E (hr)
RU (2) RU2449995C2 (hr)
SG (1) SG153811A1 (hr)
SI (1) SI1755606T2 (hr)
TN (1) TNSN06405A1 (hr)
WO (1) WO2005120510A1 (hr)
ZA (1) ZA200609634B (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CN101506210A (zh) 2006-08-23 2009-08-12 神经能质公司 2-苯氧基嘧啶酮类似物
WO2008066664A2 (en) * 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
EP2178562B1 (en) 2007-07-18 2017-08-23 Novartis AG Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
US8915362B2 (en) 2008-10-08 2014-12-23 Ultimed, Inc. Sharps container
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
JP2016510749A (ja) 2013-03-05 2016-04-11 ユニヴァーシティー オブ ノートル ダム デュ ラック キナゾリノン抗生物質
US10016425B2 (en) 2016-11-03 2018-07-10 King Saud University Anti-ulcerative colitis compound
EP3873903B1 (en) 2018-10-31 2024-01-24 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CA3130038A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
EP4431497A1 (en) 2019-02-15 2024-09-18 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN116419918A (zh) 2020-08-06 2023-07-11 诺华股份有限公司 4-(7-羟基-2-异丙基-4-氧代-4h-喹唑啉-3-基)-苄腈的结晶形式及其配制品
WO2022105792A1 (zh) * 2020-11-17 2022-05-27 苏州晶云药物科技股份有限公司 一种喹唑啉酮衍生物的新晶型及其制备方法
UY39681A (es) 2021-03-26 2022-10-31 Novartis Ag Derivados de ciclobutilo 1,3–sustituidos y sus usos
WO2024062389A1 (en) 2022-09-21 2024-03-28 Bausch + Lomb Ireland Limited Crystalline polymorph forms of a trpv1 antagonist and formulations thereof

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US220227A (en) * 1879-10-07 Improvement in stri klng-movements for clocks
US49728A (en) * 1865-09-05 Improvement
US82365A (en) * 1868-09-22 thompson
US95650A (en) * 1869-10-12 Improvement in machines for bending sheet-metal for cornices
DE239090C (hr) 1906-11-01
US2749344A (en) * 1953-01-02 1956-06-05 Burroughs Wellcome Co Pyrimidine compounds
DE1224316B (de) 1961-03-18 1966-09-08 Beiersdorf & Co Ag P Verfahren zur Herstellung von 2-Methyl-3-(o-aethylphenyl)-4-oxo-3, 4-dihydrochinazolin und dessen Salzen
DE1232152B (de) * 1962-06-27 1967-01-12 Heyden Chem Fab Verfahren zur Herstellung von 3-Phenylchinazolinon-(4)-derivaten
US3515787A (en) * 1962-06-27 1970-06-02 Squibb & Sons Inc Compositions and methods for producing a muscle relaxing effect in an animal with 2,3 - substituted - 6 - amino-4-quinazolones
GB1003802A (en) * 1963-06-04 1965-09-08 Searle & Co Pyrimidinone derivatives
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US3317388A (en) * 1964-11-20 1967-05-02 Wallace & Tiernan Inc Methods for treating pain
US3864362A (en) * 1970-05-27 1975-02-04 Chinoin Gyogyszer Es Vegyeszet Iso flavones
BE793594A (fr) 1972-01-03 1973-07-02 Pfizer Nouvelles 6,7-dimethoxyquinazolines utiles comme analgesiques et tranquillisants
GB1495305A (en) 1975-09-12 1977-12-14 Pfizer Ltd 3-phenyl-4-oxo-4h-benzopyran derivatives
US4501755A (en) * 1981-05-01 1985-02-26 Pennwalt Corporation Isoflavones useful as anti-inflammatory agents
JPS59128376A (ja) * 1983-01-13 1984-07-24 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
SU1262927A1 (ru) 1985-01-09 1997-11-20 Институт физико-органической химии и углехимии АН УССР Способ получения 6-бром-5-метилимидазо(4,5-в)пиридина
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPS62193605A (ja) * 1986-02-20 1987-08-25 Toray Ind Inc 半透性複合膜の製造方法
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US5290780A (en) * 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
WO1992013535A1 (en) * 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5284853A (en) * 1993-04-23 1994-02-08 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0635263A3 (en) * 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
HUT68558A (en) 1993-07-20 1995-06-28 Chinoin Gyogyszer Es Vegyeszet Method for preparing isoflavon derivatives
JPH09510695A (ja) 1994-01-03 1997-10-28 エイシア・ファーマシュウティカルズ，インコーポレイテッド ８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用
JPH07258224A (ja) 1994-03-24 1995-10-09 Dai Ichi Seiyaku Co Ltd 二環性化合物
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
AU704544B2 (en) * 1995-03-14 1999-04-29 Novartis Ag Trisubstituted phenyl derivatives
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
AU712019B2 (en) 1996-05-20 1999-10-28 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
AU6908398A (en) 1996-10-28 1998-05-22 Versicor Inc Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones
IT1289154B1 (it) 1997-01-03 1998-09-29 Chiesi Farma Spa Derivati di isoflavone loro preparazione e loro impiego terapeutico
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
US5948775A (en) 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
DE69819345T2 (de) 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
JP2002503451A (ja) 1998-01-22 2002-02-05 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア カプサイシン受容体をコードする核酸配列
WO1999043654A2 (en) 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EP1154989B1 (en) * 1999-02-22 2005-12-14 Pacific Corporation Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
WO2001070228A1 (en) 2000-03-17 2001-09-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
MXPA03000458A (es) * 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
CN100439332C (zh) * 2000-08-21 2008-12-03 株式会社太平洋 硫脲衍生物以及包含该衍生物的药物组合物
FR2815033B1 (fr) 2000-10-06 2003-09-05 Negma Lab Derives de 7-carboxy-flavones, porcede pour leur preparation et leur application en therapeutique
AU2001297717B2 (en) 2000-12-11 2006-02-23 Amgen Inc. CXCR3 antagonists
WO2002076946A2 (en) 2001-03-26 2002-10-03 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
JP2005501873A (ja) 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
AU2003238157A1 (en) * 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
BR0312461A (pt) 2002-07-05 2005-04-26 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003291761A1 (en) 2002-11-04 2004-06-07 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005040112A1 (en) 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
JP2007511496A (ja) † 2003-11-14 2007-05-10 メルク シャープ エンド ドーム リミテッド バニロイド−１受容体（ｖｒ１）の機能を調節する二環式ピリミジン−４−（３ｈ）−オン類並びにその類似体及び誘導体
EP1717230B1 (en) 2004-02-13 2014-08-06 Msd K.K. Fused-ring 4-oxopyrimidine derivative
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US20090298856A1 (en) 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP2178562B1 (en) 2007-07-18 2017-08-23 Novartis AG Synergistic combinations of vr-1 antagonists and cox-2 inhibitors
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists

Also Published As

Publication number Publication date
US20120184571A1 (en) 2012-07-19
AU2005251476A1 (en) 2005-12-22
DE602005003128T3 (de) 2012-02-09
SG153811A1 (en) 2009-07-29
RU2449995C2 (ru) 2012-05-10
HK1105577A1 (en) 2008-02-22
EP1755606A1 (en) 2007-02-28
US20080194595A1 (en) 2008-08-14
SI1755606T2 (sl) 2011-10-28
ECSP12007067A (es) 2012-03-30
TNSN06405A1 (en) 2008-02-22
US20140315932A1 (en) 2014-10-23
US8211902B2 (en) 2012-07-03
JP4703650B2 (ja) 2011-06-15
MXPA06014249A (es) 2007-02-19
MA28685B1 (fr) 2007-06-01
IL179532A (en) 2012-12-31
CN1956721A (zh) 2007-05-02
ATE376833T1 (de) 2007-11-15
KR20100101017A (ko) 2010-09-15
EP1755606B1 (en) 2007-10-31
US8809528B2 (en) 2014-08-19
NZ551630A (en) 2010-08-27
RU2010112450A (ru) 2011-10-10
CA2567821C (en) 2013-12-24
HRP20070577T3 (hr) 2008-08-31
WO2005120510A1 (en) 2005-12-22
RU2396261C2 (ru) 2010-08-10
JP2008501763A (ja) 2008-01-24
CN1956721B (zh) 2015-05-13
BRPI0511933B8 (pt) 2021-05-25
RU2006146632A (ru) 2008-07-20
ES2293584T3 (es) 2008-03-16
ES2293584T5 (es) 2011-11-23
US20110195983A1 (en) 2011-08-11
JP5400812B2 (ja) 2014-01-29
PL1755606T5 (pl) 2011-11-30
KR101018607B1 (ko) 2011-03-04
KR20070021244A (ko) 2007-02-22
DE602005003128D1 (de) 2007-12-13
US7960399B2 (en) 2011-06-14
SI1755606T1 (sl) 2008-08-31
US9102653B2 (en) 2015-08-11
PT1755606E (pt) 2008-01-21
BRPI0511933B1 (pt) 2019-04-24
DK1755606T3 (da) 2008-03-03
AU2005251476C1 (en) 2011-09-15
AU2005251476B2 (en) 2009-12-03
DK1755606T4 (da) 2011-10-24
BRPI0511933A (pt) 2008-01-22
GB0412769D0 (en) 2004-07-07
ZA200609634B (en) 2008-08-27
NO338181B1 (no) 2016-08-01
CY1107846T1 (el) 2013-06-19
EP1755606B2 (en) 2011-06-29
PL1755606T3 (pl) 2008-03-31
DE602005003128T2 (de) 2008-08-07
IL179532A0 (en) 2007-05-15
CA2567821A1 (en) 2005-12-22
JP2011105738A (ja) 2011-06-02
NO20070122L (no) 2007-03-01
ECSP067067A (es) 2007-01-26
AU2009233684A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
HRP20070577T4 (hr) Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida
RS51136B (sr) Supstituisani pirolopiridini, kompozicije koje ih sadrže, postupak za njihovo dobijanje i upotreba
HRP20120867T1 (hr) Selurampanel
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
ME01089B (me) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
HRP20110349T1 (hr) Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma
RS51516B (en) ADDITIONAL HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
RS52042B (en) FUNGICID MIXTURES
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
SE0301009D0 (sv) Novel compounds
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
SE0403171D0 (sv) New compounds
RS53389B (en) PHARMACEUTICAL UNITS
HRP20120634T1 (hr) Antibiotik 107891, njegovi faktori, farmaceutski prihvatljive soli i sastavi, te njihova uporaba
WO2006117314A3 (en) Novel piperidin- substituted indoles and their use as ccr-3 modulators
DE502005007850D1 (de) Substituierte cyclohexyl-1,4-diamin-derivate
TW200613279A (en) New pesticides